KRAS and cancer: Sequencing analysis of MM patient samples has shown that the Kirsten RAS (KRAS) oncogene is the most commonly mutated gene (36%) in the disease, followed by the neuroblastoma RAS (NRAS) (20%), with frequent co-existence of one or more variants in both KRAS and NRAS cancer-driver genes (4–6).